Development cohort n=55 | Validation cohort n=28 | p | |
---|---|---|---|
Birthweight (g) | 920 (580-2256) | 1044 (520-1720) | 0.46 |
Gestational age (weeks) | 28 (23-31) | 29 (24-31) | 0.054 |
Antenatal steroids | 44 (80) | 27 (96) | 0.09 |
Prophylactic indomethacin | 11 (20) | 13 (46) | 0.02 |
Male sex | 29 (53) | 17 (61) | 0.64 |
FIO2 (%) | 40 (21-100) | 60 (22-100) | 0.07 |
a:A ratio | 0.22 (0.04-0.67) | 0.15 (0.09-0.46) | 0.21 |
PIP (cm H2O) | 14 (10-29) | 20 (12-28) | 0.002 |
AT:RVET(c) | 0.47 (0.37-0.53) | 0.45 (0.25-0.68) | 0.51 |
Symptomatic PDA | 9 (16) | 3 (11) | 0.71 |
Ductal shunting | 10 (38)3-151 | ||
CLD | 19 (35) | 17 (61) | 0.04 |
Deaths | 7 (13) | 6 (21) | 0.48 |